Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment reporting

Analytics

Phase 2

4(44.4%)

Phase 1

2(22.2%)

Phase 3

1(11.1%)

Early Phase 1

1(11.1%)

N/A

1(11.1%)

9Total

Phase 2(4)

Phase 1(2)

Phase 3(1)

Early Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07007325Early Phase 1Not Yet Recruiting

Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)

Role: lead

NCT07260162Phase 1Not Yet Recruiting

Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)

Role: lead

NCT02890082Phase 2Active Not Recruiting

Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer

Role: lead

NCT05840562Phase 3Recruiting

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Role: lead

NCT06967987Phase 2Withdrawn

Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b

Role: lead

NCT06962163Not ApplicableRecruiting

Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients

Role: lead

NCT06681038Phase 2Not Yet Recruiting

Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)

Role: lead

SYF3a4a827119c64af0b86790f8bbb71b16Phase 1Unknown

ExplOratory, Phase 0 Study to assess biodisTribution and PosItron EMission Tomography (PET) Imaging kinetics of [64Cu]Cu-PSMA-R2 in metaStatic prostate cancEr patients

Role: lead

SYF553de746aeff406198b385424602bac4Phase 2Unknown

PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer

Role: lead

All 9 trials loaded